Research and Markets has announced the addition of "Egis Generics Company Intelligence Report" to their offering.
Egis Nyrt was established in Budapest, Hungary, in 1913. The company has three manufacturing sites: two in Budapest, and one at Körmend, near the border with Austria. The company has 18 subsidiaries under its direct control. Six are in Hungary, with the remaining 12 abroad. Additionally, Egis has seven indirect subsidiaries, all of which are in Hungary, and 20 representative offices across the world. Egis has been listed on the Budapest Stock Exchange (BÉT) since 1994. However, Hungarian investors only make up around 6% of its ownership.
The majority owner is the French firm, Servier, which has 51% of Egis’ shares. Egis acts as a distributor for Servier in Hungary, and supplies generics to France through Servier’s generic subsidiary. It also markets products through Servier’s subsidiaries in the United Kingdom. Egis reported total sales in fiscal year 2005 worth Ft 72,959.9 million ($377.2 million). This was an increase of 10% over fiscal year 2004, when sales were worth Ft 66,107.6 million. Net income reached Ft 11,384.2 million ($58.6 million), over 54% higher than a year earlier.
Exports accounted for Ft 43,216 million ($223.4 million), or 59% of Egis’ total sales. Outside of Hungary, the company’s largest markets are those of Russia and the CIS, and Central and Eastern Europe. These generics company reports from Espicom will help you to understand the dynamic and complex issues affecting the business of leading generic industry players.
These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company’s active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. The easy and cost effective way to monitor developments in leading generic drug industry players. Generics Company Reports are packed with facts, figures and statistics, providing you with the most thorough ongoing monitoring of the important generic companies.
From financial performance to litigation, no other service provides such comprehensive insight to the companies driving growth in this rapidly expanding area of the pharmaceutical industry. Each report is updated and issued every quarter. This ongoing monitoring and regular delivery ensures that developments are incorporated into the relevant reports. This vigilance ensures that whether it’s the latest deals, ANDAs, alliances or litigation you can assess the impact of the development in the context of the company, its competitors and the broader market. (genengnews.com)